Who to call at Cingulate Inc., and when
Fundz watches for the moments Cingulate Inc. starts buying, and tells you who to reach.
- An alert the day Cingulate Inc. raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Cingulate Inc., from your own LinkedIn network
Cingulate Inc.
A senior executive or director joined, left, or changed roles. An 8-K is the notice a US public company must file within four business days of a major event.
www.cingulate.comAI Executive Summary
AI-powered analysis of 8-K filing content
Cingulate Inc. appointed Matthew N. Brams as Executive Vice President and Chief Medical Officer on September 30, 2026, following an amendment to his employment agreement effective January 1, 2026. This leadership appointment is intended to strengthen the company's medical strategy and clinical development capabilities in the biopharmaceutical sector.
Key Takeaways
Matthew N. Brams elevated to Executive Vice President and Chief Medical Officer role
Employment agreement amendment No. 2 executed, effective retroactively from January 1, 2026
2 more takeaways
Filing Overview
What This Means
Cingulate Inc. filed with the SEC. Fundz turns 8-K material events into an alert with the right executive attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
4 screens from a live account. No signup.